According to Zacks, “Amneal Pharmaceuticals LLC is an integrated specialty pharmaceutical company. It focused on developing, manufacturing and distributing generic, brand and biosimilar products. The company operates primarily in North America, Asia and Europe. Amneal Pharmaceuticals LLC, formerly known as Impax Laboratories Inc., is based in New Jersey, United States. “
Several other equities research analysts also recently issued reports on the stock. Barclays set a $5.00 price objective on shares of Amneal Pharmaceuticals and gave the stock a hold rating in a research note on Thursday, July 11th. Cantor Fitzgerald decreased their target price on shares of Amneal Pharmaceuticals from $35.00 to $14.00 and set an overweight rating for the company in a research note on Wednesday, June 12th. SunTrust Banks restated a buy rating and issued a $5.00 target price on shares of Amneal Pharmaceuticals in a research note on Tuesday, August 6th. Leerink Swann upgraded shares of Amneal Pharmaceuticals from a market perform rating to an outperform rating in a research note on Monday, July 22nd. Finally, BMO Capital Markets decreased their target price on shares of Amneal Pharmaceuticals from $6.00 to $5.00 and set a market perform rating for the company in a research note on Tuesday, August 6th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the stock. Amneal Pharmaceuticals presently has a consensus rating of Hold and an average price target of $9.00.
Amneal Pharmaceuticals (NYSE:AMRX) last released its quarterly earnings data on Monday, August 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.14 by ($0.05). Amneal Pharmaceuticals had a positive return on equity of 28.20% and a negative net margin of 3.65%. The business had revenue of $404.60 million for the quarter, compared to analysts’ expectations of $420.12 million. During the same quarter in the prior year, the firm earned $0.24 earnings per share. Amneal Pharmaceuticals’s quarterly revenue was down 12.5% compared to the same quarter last year. Research analysts anticipate that Amneal Pharmaceuticals will post 0.51 earnings per share for the current year.
In related news, SVP Pradeep Bhadauria acquired 30,000 shares of Amneal Pharmaceuticals stock in a transaction on Friday, August 16th. The shares were purchased at an average cost of $2.41 per share, for a total transaction of $72,300.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Ted C. Nark acquired 50,000 shares of Amneal Pharmaceuticals stock in a transaction on Wednesday, August 28th. The shares were bought at an average price of $2.39 per share, for a total transaction of $119,500.00. The disclosure for this purchase can be found here. Insiders bought 1,788,966 shares of company stock valued at $5,377,057 over the last 90 days. Insiders own 26.34% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Swiss National Bank boosted its stake in Amneal Pharmaceuticals by 2.1% during the 2nd quarter. Swiss National Bank now owns 171,200 shares of the company’s stock valued at $1,228,000 after acquiring an additional 3,600 shares during the last quarter. New York State Common Retirement Fund boosted its stake in Amneal Pharmaceuticals by 27.3% during the 1st quarter. New York State Common Retirement Fund now owns 108,616 shares of the company’s stock valued at $1,539,000 after acquiring an additional 23,316 shares during the last quarter. Atria Investments LLC bought a new position in Amneal Pharmaceuticals during the 2nd quarter valued at $240,000. SG Americas Securities LLC bought a new position in Amneal Pharmaceuticals during the 2nd quarter valued at $1,906,000. Finally, Marshall Wace LLP boosted its stake in Amneal Pharmaceuticals by 487.8% during the 1st quarter. Marshall Wace LLP now owns 492,275 shares of the company’s stock valued at $6,977,000 after acquiring an additional 408,533 shares during the last quarter. Hedge funds and other institutional investors own 34.79% of the company’s stock.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.